Jorge Barrero, MD
Nephrology · Oakland Park, FLNPI 1962450346
Payments from drug & device makers
Across 419 payments — averaging $23.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- OPKO Pharmaceuticals, LLC$1K
- Amgen$1K
- Vifor Pharma, Inc.$645
- Otsuka America Pharmaceutical, Inc.$644
- Bayer$602
- plus $4K from 28 others
What the payments were for
- Food & beverage$9,64899%
- Education$1281%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 78 | $1,647 |
| OPKO Pharmaceuticals, LLC | 56 | $1,285 |
| Amgen(2 entities) | 43 | $1,078 |
| Vifor Pharma, Inc. | 38 | $645 |
| Otsuka America Pharmaceutical, Inc. | 27 | $644 |
| Bayer | 22 | $602 |
| Travere Therapeutics, Inc. | 24 | $508 |
| Akebia Therapeutics Inc | 22 | $445 |
| Mallinckrodt Hospital Products Inc. | 14 | $371 |
| Calliditas Therapeutics US Inc. | 7 | $295 |
| Fresenius USA Marketing, Inc. | 13 | $245 |
| Baxter Healthcare | 4 | $239 |
| Ardelyx, Inc. | 9 | $209 |
| GSK | 7 | $204 |
| Boehringer Ingelheim | 7 | $167 |
| Novo Nordisk | 6 | $158 |
| Novartis | 6 | $150 |
| Aurinia Pharma U.S., Inc. | 7 | $147 |
| Bard Peripheral Vascular, Inc. | 2 | $139 |
| Mallinckrodt Enterprises LLC | 4 | $108 |
| Shield Therapeutics Inc | 5 | $83 |
| Shire North American Group Inc | 3 | $53 |
| Ultragenyx Pharmaceutical Inc. | 2 | $48 |
| Pfizer | 2 | $46 |
| Medtronic | 1 | $43 |
| Idorsia Pharmaceuticals US Inc | 2 | $37 |
| Vantive US Healthcare LLC | 1 | $31 |
| Alnylam Pharmaceuticals Inc. | 1 | $29 |
| Johnson & Johnson | 1 | $23 |
| Sanofi | 1 | $22 |
| Lilly USA, LLC | 1 | $21 |
| Paratek Pharmaceuticals, Inc. | 1 | $21 |
| Cormedix Inc. | 1 | $20 |
| Cumberland Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Renal - PD$123
- JESDUVROQ$119
- TARPEYO$117
- LOKELMA$117
- Kerendia$104
How this compares
$9,776 in reported general payments places this provider in the 80th percentile of 756 nephrology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FilspariSparsentan | 34 | $392,816 |
| FarxigaDapagliflozin Propanediol | 131 | $139,659 |
| RayaldeeCalcifediol | 90 | $136,029 |
| VelphoroSucroferric Oxyhydroxide | 21 | $101,084 |
| Tolvaptan | 25 | $92,706 |
| AuryxiaFerric Citrate | 38 | $83,014 |
| JardianceEmpagliflozin | 61 | $74,571 |
| KerendiaFinerenone | 60 | $54,694 |
| OzempicSemaglutide | 41 | $54,015 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 11 | $43,094 |
| VeltassaPatiromer Calcium Sorbitex | 22 | $34,482 |
| XphozahTenapanor Hcl | 11 | $34,208 |
| EliquisApixaban | 24 | $31,458 |
| LokelmaSodium Zirconium Cyclosilicate | 33 | $29,199 |
| ProsolParenteral Amino Acid 20% No.1 | 151 | $26,242 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Travere Therapeutics, Inc.Filspari | $508 | $392,81634 claims |
| AstraZenecaFarxiga, Lokelma | $1,647 | $168,858164 claims |
| OPKO Pharmaceuticals, LLCRayaldee | $1,285 | $136,02990 claims |
| Fresenius USA Marketing, Inc.Velphoro | $245 | $101,08421 claims |
| Boehringer IngelheimJardiance, Tradjenta | $167 | $89,21572 claims |
| Akebia Therapeutics IncAuryxia | $445 | $83,01438 claims |
| BayerKerendia | $602 | $54,69460 claims |
| Novo NordiskOzempic | $158 | $54,01541 claims |
| PfizerEliquis, Retacrit | $46 | $34,05235 claims |
| Johnson & JohnsonProcrit | $23 | $12,31319 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 756 nephrology providers in Florida.
Other nephrology in Oakland Park
- Thomas MarburyOrlando$41.1M
- Julio VijilHollywood$16.1M
- Steven ZeigHollywood$14.3M
- Oscar GalvezMiami$14.2M
- Jesus NavarroTampa$13.3M
- Arvind MadanOrlando$9.7M
- David HalpertAtlantis$4.2M
- Wayne KotzkerFort Lauderdale$3.4M
- Edouard MartinLauderdale Lakes$2.7M
- Jorge PosadaCoral Gables$2.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.